AVROBIO, Inc. AVRO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

AVROBIO, Inc. (AVRO) reported total assets of $261.04M and total liabilities of $9.71M for fiscal year 2025, resulting in total equity of $251.33M.

The company held $253.8M in cash and short-term investments. Total debt stood at $1.28M, with net debt of $-252.52M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 26.63, indicating strong short-term liquidity. Interest coverage is -1333.9x (weak).

Criteria supported by this page:

HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (28/100) — Total assets $261.04M and equity $251.33M support the company's competitive scale

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

AVROBIO, Inc. Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$261.04M	$152.91M	$101.09M	$103.95M
Total Liabilities	$9.71M	$12.13M	$6.35M	$28.58M
Total Debt	$1.28M	$3.3M	$878K	$17.46M
Cash & Investments	$253.8M	$141.24M	$98.3M	$92.56M
Total Stockholders Equity	$251.33M	$140.78M	$94.74M	$75.37M